Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-\u03b1 inhibitors such as Janssen \/ Merck\u2019s Remicade and AbbVie \/ Eisai\u2019s Humira helped to advance UC treatment, particularly for the moderate to severe population, and are now well entrenched as first-line biologics. However, over the past three years, the UC treatment landscape in Europe has seen the approval of the first non-TNF biologic (Takeda\u2019s Entyvio), the first targeted oral therapy for UC (Pfizer\u2019s Xeljanz), and the launch of biosimilar infliximab and adalimumab (Celltrion\u2019s Remsima and Amgen\u2019s Amgevita, respectively). Entyvio, a CAM-inhibitor, and Xeljanz, a Jak-inhibitor, offer alternative mechanisms of action for TNF-\u03b1 refractory patients, expanding the treatment armamentarium. The availability of biosimilars has influenced physicians\u2019 prescribing behavior and will continue to impact the UC treatment landscape.<\/p>\n
Questions Answered:<\/strong><\/p>\n Markets covered: <\/strong>France, Germany, Italy, Spain, and United Kingdom<\/p>\n Primary research:<\/strong> 250 gastroenterologists completed the survey. Of that total, 50 respondents were in France, 50 in Germany, 50 in Italy, 50 in Spain, and 50 in the United Kingdom. The survey was fielded from June 18 to July 14, 2019.<\/a><\/p>\n\n